©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Dec 26, 2024; 16(12): 776-780
Published online Dec 26, 2024. doi: 10.4330/wjc.v16.i12.776
Published online Dec 26, 2024. doi: 10.4330/wjc.v16.i12.776
Comparative breakthrough: Umbilical cord mesenchymal stem cells vs bone marrow mesenchymal stem cells in heart failure treatment
Peng Li, Department of Geriatics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Author contributions: Li P performed the research and wrote this manuscript.
Supported by National High Level Hospital Clinical Research Funding Project, No. BJ-2023-206.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Peng Li, MD, Doctor, Department of Geriatics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dongdan, Dahua Road, Dongcheng District, Beijing 100730, China.
Received: August 6, 2024
Revised: September 21, 2024
Accepted: November 6, 2024
Published online: December 26, 2024
Processing time: 112 Days and 6.6 Hours
Revised: September 21, 2024
Accepted: November 6, 2024
Published online: December 26, 2024
Processing time: 112 Days and 6.6 Hours
Core Tip
Core Tip: This article provides a comparative analysis of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) for the treatment of heart failure. UC-MSCs significantly increase left ventricular ejection fraction and exhibit a favorable safety profile, positioning them as a promising alternative to BM-MSCs. Future research should focus on optimizing administration protocols and understanding the long-term benefits of UC-MSCs in cardiac therapy.